注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Inhibikase Therapeutics Inc是一家临床阶段的制药公司。该公司专注于开发帕金森病(PD)以及大脑内外发生的相关紊乱的治疗方法。该公司的候选产品包括IkT-148009、IkT-001pro和IKT-01427。其主要候选产品IkT-148009是一种脑渗透性Abelson酪氨酸激酶(c-Abl)抑制剂,可阻止疾病进展并逆转大脑功能丧失和胃肠道(GI)神经功能障碍。其IkT-148009用于治疗PD,包括其在胃肠道中的表现。其候选产品IKT-001Pro是抗癌药伊马替尼的前药,该药物用于治疗慢性骨髓性白血病(CML)。IKT-01427是一种口服脑渗透药物,旨在阻止约翰坎宁安(JC)病毒进入细胞,从而阻止其在体内复制的能力。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Milton H. Werner | 59 | 2010 | CEO, President & Director |
Roy Lester Freeman | 70 | 2020 | Independent Director |
Valina L. Dawson | - | - | Member of Scientific Advisory Board |
Gisele Dion | 56 | 2022 | Independent Director |
Charles Warren Olanow | - | - | CEO of Clintrex Research Corporation & Member of Scientific Advisory Board |
Paul C. Grint | 65 | 2020 | Independent Director |
Karl Kieburtz | - | - | Member of Scientific Advisory Board |
Jeffrey H. Kordower | - | - | Member of Scientific Advisory Board |
Kenneth L. Marek | - | - | Member of Scientific Advisory Board |
Pankaj Jay Pasricha | - | - | Member of Scientific Advisory Board |
Robert A. Hauser | - | - | Member of Scientific Advisory Board |
Dennis N. Berman | 72 | 2020 | Independent Director |
Ted M. Dawson | - | - | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核